Robert Passas Ph.D. Appointed President, EMEA and
APAC RegionsSharon Klugewicz Appointed President, Americas
Region
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care
(POC) diagnostic tests for infectious diseases, announced today the
appointment of two senior leadership positions to support the
expansion of the company's global commercial operations.
Effective today, Robert Passas, Ph.D., has joined the company as
President, EMEA and APAC regions, with responsibility for
commercial operations in Europe, Middle East, Africa, and
Asia. Sharon Klugewicz, most recently the Company's Chief
Operating Officer, has been promoted to President, Americas region,
with responsibility for commercial operations in the United States,
Latin America, and Canada.
Dr. Passas joins Chembio today, bringing an
established track record and expertise in clinical diagnostics,
which includes over 25 years of general management and commercial
operations. As President of Chembio’s EMEA and APAC regions, he
will be responsible for sales, marketing, and customer support and
will be tasked with establishing regional sales and marketing,
building country-specific distribution channels, and increasing
sales throughout the regions. Prior to joining the company, he held
positions of increasing responsibility at Abbott, Quidel, The
Binding Site, and Trinity Biotech. In his most recent position, he
was responsible for worldwide marketing and international sales at
Trinity Biotech. Dr. Passas holds a B.S. in medical biochemistry
and a Ph.D. in analytical chemistry from the University of Surrey,
U.K.
Chembio CEO John Sperzel commented, “We are
delighted to add someone of Bob’s caliber to our commercial
leadership team at a time when our product portfolio is expanding
beyond sexually transmitted disease, to include future POC tests
for fever and tropical diseases such as Malaria, Dengue, Zika,
Chikungunya, Ebola, Lassa and Marburg. He has significant industry
experience in commercial operations, having worked for several of
the world’s leading diagnostic companies, and a track record of
building highly effective worldwide sales and marketing teams. We
expect Bob to make an immediate impact by creating the framework
for commercial success throughout the EMEA and APAC regions.”
Ms. Klugewicz joined Chembio in 2012 and
demonstrated success and leadership in multiple roles, including
her most recent position as Chief Operating Officer. As President
of Chembio’s Americas region, she will be responsible for sales,
marketing, customer support, clinical and regulatory affairs, and
quality systems in the Americas, and will be tasked with leading
the U.S. commercial team and expanding commercial operations
throughout Latin America, the U.S. and Canada. Prior to joining the
company, she spent 20 years at Pall Corporation where she held
positions of increasing responsibility, including Senior Vice
President, Scientific and Laboratory Services. Ms. Klugewicz
received a B.S. in Neurobiology from Stony Brook University and a
M.S. in Biochemistry from Adelphi University.
Mr. Sperzel further commented, “Since joining
Chembio, Sharon has established a track record of success in a
number of areas, including manufacturing, product development,
regulatory affairs, and quality systems. I’ve had the pleasure of
working closely with her since 2014, and she has demonstrated the
right combination of skills, knowledge and attributes to assume the
leadership of commercial operations in the Americas region.”
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops,
manufactures, licenses and markets proprietary rapid diagnostic
tests in the growing $8.0 billion point-of-care testing
market. Chembio markets each of its DPP® HIV 1/2 Assay, HIV
1/2 STAT-PAK® Assay, and SURE CHECK® HIV 1/2 Assay, with these
Chembio brand names, in the U.S. and internationally both directly
and through third-party distributors. The Company's SURE
CHECK® HIV 1/2 Assay previously has been exclusively sold in the
U.S. as Clearview® Complete HIV 1/2 Assay.
Chembio has developed a patented point-of-care
(POC) test platform technology, the Dual Path Platform (DPP®)
technology, which has significant advantages over lateral-flow
technologies. This technology is providing Chembio with a
significant pipeline of business opportunities for the development
and manufacture of new products.
Headquartered in Medford, NY, Chembio is
licensed by the U.S. Food and Drug Administration (FDA) as well as
the U.S. Department of Agriculture (USDA), and is certified for the
global market under the International Standards Organization (ISO)
directive 13485. Chembio Diagnostic Systems Inc. is a wholly-owned
subsidiary of Chembio Diagnostics, Inc. For more information,
please visit: www.chembio.com.
Forward-Looking Statements
Statements contained herein that are not
historical facts may be forward-looking statements within the
meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current
views, are based on certain assumptions, and involve risks and
uncertainties. Actual results, events, or performance may differ
materially from the above forward-looking statements due to a
number of important factors, and will be dependent upon a variety
of factors, including, but not limited to Chembio's ability to
obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products.
Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that
occur after the date hereof or to reflect any change in Chembio's
expectations with regard to these forward-looking statements or the
occurrence of unanticipated events. Factors that may impact
Chembio's success are more fully disclosed in Chembio's most recent
public filings with the U.S. Securities and Exchange
Commission.
Contacts:
Chembio Diagnostics
Susan Norcott
(631) 924-1135, ext. 125
snorcott@chembio.com
Vida Strategic Partners (investor relations)
Stephanie C. Diaz
(415) 675-7401
sdiaz@vidasp.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2024 to May 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From May 2023 to May 2024